LGL Group (LGL) Expected to Announce Quarterly Earnings on Thursday

Posted by Geri Gentry on Aug 11th, 2026

LGL Group (NYSEAMERICAN:LGL – Get Free Report) is expected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect LGL Group to announce earnings of $0.01 per share and revenue of $0.80 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 17, 2026 at 4:00 PM ET.

LGL Group Stock Up 3.2%

LGL stock opened at $7.33 on Tuesday. The company has a market cap of $47.94 million, a price-to-earnings ratio of 733.73 and a beta of 0.32. The business has a fifty day simple moving average of $6.94 and a 200-day simple moving average of $7.05. LGL Group has a 52 week low of $5.45 and a 52 week high of $7.57.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded LGL Group to a “hold” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, LGL Group currently has an average rating of “Hold”.

Check Out Our Latest Report on LGL Group

Institutional Trading of LGL Group

An institutional investor recently raised its position in LGL Group stock. Osaic Holdings Inc. boosted its position in LGL Group, Inc. (The) (NYSEAMERICAN:LGL – Free Report) by 15.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,250 shares of the industrial products company’s stock after buying an additional 2,710 shares during the quarter. Osaic Holdings Inc. owned 0.38% of LGL Group worth $154,000 at the end of the most recent quarter. 30.28% of the stock is currently owned by institutional investors.

About LGL Group

(Get Free Report)

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.